BNP Paribas Asset Management
EWTX icon

BNP Paribas Asset Management’s Edgewise Therapeutics EWTX Stock Holding History

BNP Paribas Asset Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.8K Sell
782
-190
-20% -$6.55K ﹤0.01% 1928
2026
Q1 		$30.6K Buy
972
+244
+34% +$7.04K ﹤0.01% 1895
2025
Q4 		$18K Buy
728
+207
+40% +$4.16K ﹤0.01% 1984
2025
Q3 		$8K Buy
521
+67
+15% +$950 ﹤0.01% 1692
2025
Q2 		$6K Buy
+454
New +$6.55K ﹤0.01% 1927

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BNP Paribas Asset Management's EWTX Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Edgewise Therapeutics (EWTX) stake by 20% in Q2 2026, selling an estimated $6.55K and leaving 782 shares worth $31.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1928.

BNP Paribas Asset Management first reported a position in EWTX in Q2 2025 and has held it in 5 quarters since. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • BNP Paribas Asset Management held 782 shares of Edgewise Therapeutics worth $31.8K as of Q2 2026.
  • BNP Paribas Asset Management sold 190 Edgewise Therapeutics shares in Q2 2026, an estimated $6.55K.
  • Edgewise Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1928 holding.
  • BNP Paribas Asset Management first reported a position in Edgewise Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.